The global Frontotemporal Dementia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.
According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause of Frontotemporal dementia is still unknown it majorly affects individuals between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 10 Million |
| Anticipated Forecast Value (2033) | US$ 17.91 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Frontotemporal Dementia Management reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Frontotemporal Dementia Management.
The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of dementia patients, increasing research and development investments, and increasing drug development grants and funding by the government, as well as non-government organizations, are propelling immense growth.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Frontotemporal Dementia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dementia and others is fuelling the market growth. Thus, the market for Frontotemporal Dementia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increased Prevalence of the Condition to Push the Market Growth
The high prevalence of dementia is driving the growth of the market owing to treatment advancements and the development of novel therapies for dementia. Furthermore, the vulnerable aging population, government incentives, and benefits through special designation. According to the Centers for Disease Control and Prevention, by 2060, the number of Alzheimer’s disease cases is predicted to rise to an estimated 14 million people, with minority populations being affected the most.
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting drug development as the patient base of Frontotemporal dementia is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia. The population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Frontotemporal Dementia Management, less awareness of the condition, lack of proper diagnosis and higher chances of misunderstanding Alzheimer’s disease, and insubstantial and poor treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Improvement in healthcare spending propelling the growth of Frontotemporal Dementia Management in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Frontotemporal Dementia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to the increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Technological Advancements Shaping Landscape for Frontotemporal Dementia Management in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. According to the Centers for Disease Control and Prevention, current estimates are that about 5.8 million people in the USA have Alzheimer’s disease and related dementias, including 5.6 million aged 65 and older and about 200,000 under age 65 with younger-onset Alzheimer’s.
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.A Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Government initiatives, an increase in the number of research partnerships, the presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Antidepressants as an effective treatment to drive the market
A study conducted by the National Center for Biotechnology Information included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses related to antidepressant efficacy. To analyze, the organization had nine groups of patients with dementia treated with antidepressants compared with nine groups receiving placebo treatment. As a result, participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks.
Considering this, FMI concludes that there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
Hospital Pharmacies to take the lead and drive market growth
According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during Frontotemporal Dementia Management facilitates the growth of this segment. The majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key start-ups in the market include-
Key players in the Frontotemporal Dementia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 10 Million |
| Market Value in 2033 | US$ 17.91 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is valued at US$ 10.1 million in 2023.
Pfizer Inc., Johnson & Johnson, and Sanofi S.A. are the vital market players.
The market is predicted to be worth US$ 17.9 million by 2033.
The high prevalence of dementia is likely to drive the market prospects.
Asia Pacific is likely to generate 5.0% revenue through 2033.
1. Executive Summary | Frontotemporal Dementia Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global analysis 2018 to 2022 and Forecast, 2023 to2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Drug Class Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class Type, 2023 to2033 5.3.1. Antidepressants 5.3.1.1. Fluoxetine 5.3.1.2. Fluvoxamine 5.3.1.3. Sertraline 5.3.1.4. Paroxetine 5.3.1.5. Citalopram 5.3.1.6. Bupropion 5.3.1.7. Mitrazepine 5.3.2. Antipsychotics 5.3.2.1. Olanzapine 5.3.2.2. Quetiapine 5.3.2.3. Ziprasidone 5.3.2.4. Aripiprazole 5.3.2.5. Risperidone 5.3.2.6. Paliperidone 5.4. Y-o-Y Growth Trend Analysis By Drug Class Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class Type, 2023 to2033 6. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to2033 6.3.1. Hospital Pharmacy 6.3.2. Retail Pharmacy 6.3.3. Drug Store 6.3.4. Online Pharmacy 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to2033 7. Global analysis 2018 to 2022 and Forecast 2023 to2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to2033 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to2033 8. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America analysis 2018 to 2022 and Forecast 2023 to2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033 9.2.1. By Country 9.2.1.1. United States of America 9.2.1.2. Canada 9.2.2. By Drug Class Type 9.2.3. By Distribution Channel 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class Type 9.3.3. By Distribution Channel 9.3.4. By End User 9.4. Key Takeaways 10. Latin America analysis 2018 to 2022 and Forecast 2023 to2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class Type 10.2.3. By Distribution Channel 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class Type 10.3.3. By Distribution Channel 10.3.4. By End User 10.4. Key Takeaways 11. Europe analysis 2018 to 2022 and Forecast 2023 to2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class Type 11.2.3. By Distribution Channel 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class Type 11.3.3. By Distribution Channel 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific analysis 2018 to 2022 and Forecast 2023 to2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Drug Class Type 12.2.3. By Distribution Channel 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class Type 12.3.3. By Distribution Channel 12.3.4. By End User 12.4. Key Takeaways 13. MEA analysis 2018 to 2022 and Forecast 2023 to2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Drug Class Type 13.2.3. By Distribution Channel 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class Type 13.3.3. By Distribution Channel 13.3.4. By End User 13.4. Key Takeaways 14. Key Country's analysis 14.1. United States of America 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Drug Class Type 14.1.2.2. By Distribution Channel 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Drug Class Type 14.2.2.2. By Distribution Channel 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Drug Class Type 14.3.2.2. By Distribution Channel 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Drug Class Type 14.4.2.2. By Distribution Channel 14.4.2.3. By End User 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Drug Class Type 14.5.2.2. By Distribution Channel 14.5.2.3. By End User 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Drug Class Type 14.6.2.2. By Distribution Channel 14.6.2.3. By End User 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Drug Class Type 14.7.2.2. By Distribution Channel 14.7.2.3. By End User 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Drug Class Type 14.8.2.2. By Distribution Channel 14.8.2.3. By End User 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Drug Class Type 14.9.2.2. By Distribution Channel 14.9.2.3. By End User 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Drug Class Type 14.10.2.2. By Distribution Channel 14.10.2.3. By End User 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Drug Class Type 14.11.2.2. By Distribution Channel 14.11.2.3. By End User 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Drug Class Type 14.12.2.2. By Distribution Channel 14.12.2.3. By End User 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Drug Class Type 14.13.2.2. By Distribution Channel 14.13.2.3. By End User 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Drug Class Type 14.14.2.2. By Distribution Channel 14.14.2.3. By End User 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Drug Class Type 14.15.2.2. By Distribution Channel 14.15.2.3. By End User 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Drug Class Type 14.16.2.2. By Distribution Channel 14.16.2.3. By End User 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Drug Class Type 14.17.2.2. By Distribution Channel 14.17.2.3. By End User 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Drug Class Type 14.18.2.2. By Distribution Channel 14.18.2.3. By End User 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Drug Class Type 14.19.2.2. By Distribution Channel 14.19.2.3. By End User 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Drug Class Type 14.20.2.2. By Distribution Channel 14.20.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Class Type 15.3.3. By Distribution Channel 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Pfizer Inc. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Novartis AG 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. F. Hoffmann-La Roche Ltd. 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. AstraZeneca GmbH 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Sanofi S.A 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Merck & Co., Inc. 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. TauRx Pharmaceuticals 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Alector Pharma Co. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Bausch Health Companies Inc. 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. GlaxoSmithKline Plc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Frontotemporal Dementia Management Market
